Current medical therapy of inflammatory bowel disease

doi:10.3748/wjg.v6.iSuppl3.7

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue Suppl3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (394)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

326

Sum=394

Sep 15, 2000 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Abstracts Open Access

World J Gastroenterol. Sep 15, 2000; 6(Suppl3): 7-7
Published online Sep 15, 2000. doi: 10.3748/wjg.v6.iSuppl3.7

Current medical therapy of inflammatory bowel disease

Kiron M Das, Sherif A Farag

Kiron M Das, Sherif A Farag, Department of Medicine, Division of Gastroenterology and Hepatology, and Crohn’s and Colitis Center of New Jersey, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08903, Germany

Author contributions: All authors contributed equally to the work.

Correspondence to: Kiron M Das, MD, PhD, Cheif, Division of Gastroenterology and Hepatology, and Crohn’s and Colitis Center of New Jersey, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08903, Germany

Telephone: 732-2357784 Fax: 732-2357792

Received: June 24, 2000
Revised: July 5, 2000
Accepted: July 10, 2000
Published online: September 15, 2000

Abstract

The current established drugs used to treat inflammatory bowel disease include glucocorticoids including newer agent budesonide, sulfasalazine and 5-ASA compounds such as Asacol, Pentasa, Dipentum and Balsalazide and immunomodulatory agents such as azathioprine, and 6-mercaptopurine. Additional drugs which have been found to be useful, particularly in refractory cases of Crohn’s disease including fistulizing type of Crohn’s disease, include cyclosporine A, methotrexate, humanized antibody against TNF-α (cA₂), FK506, IL-10, IL-11 and Probiotics. Various agents, whether used alone or in combination, have to be tailored for each patient and none is ideal. Exciting new developments directed against proinflammatory pathways, cytokines, free oxygen radicals and cell surface related immune targets are areas of intense recent investigations and many novel therapeutic agents are expected to be available in the near future for medical treatment of inflammatory bowel disease.

Key Words: Inflammatory bowel disease, Medical therapy, Glucocorticoids, Budesonide, Sulfasalazine, Crohn’s disease

Citation: Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000; 6(Suppl3): 7-7
URL: https://www.wjgnet.com/1007-9327/full/v6/iSuppl3/7.htm
DOI: https://dx.doi.org/10.3748/wjg.v6.iSuppl3.7

Footnotes

E- Editor: Hu S